ALK and non-small cell lung carcinoma: Consequently, the role of targeted therapies in the context of operable NSCLC has recently gained attention following the landmark trials of tyrosine-kinase inhibitors (TKIs) (ADAURA, ALINA), which led to FDA approval for osimertinib and alectinib in the adjuvant treatment of EGFR- and ALK-positive disease, respectively.